Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from TYK Medicines, Inc. Class H ( (HK:2410) ) is now available.
TYK Medicines, Inc has announced its 2024 Annual General Meeting (AGM) to be held on June 26, 2025, in Shanghai. The meeting will address several resolutions, including the approval of the 2024 reports and financial statements, remuneration for directors and supervisors, and the appointment of Dr. Zhu Xiangyang as a non-executive director. Additionally, the AGM will consider the re-appointment of Ernst & Young as auditors and discuss mandates related to share issuance and repurchase, as well as amendments to the Articles of Association. These resolutions are pivotal for the company’s governance and strategic direction, impacting its operational and financial planning.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and distributing medicinal products.
Average Trading Volume: 2,158,311
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$8.08B
For a thorough assessment of 2410 stock, go to TipRanks’ Stock Analysis page.